Shares of ASLAN PHARMACEU/ADR (NASDAQ:ASLN) have been assigned a consensus broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and three have assigned a strong buy recommendation to the company.
Brokers have set a 1 year consensus price objective of $8.88 for the company and are expecting that the company will post ($0.20) earnings per share for the current quarter, according to Zacks. Zacks has also given ASLAN PHARMACEU/ADR an industry rank of 78 out of 256 based on the ratings given to related companies.
A number of research firms recently weighed in on ASLN. Zacks Investment Research upgraded shares of ASLAN PHARMACEU/ADR from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Monday, May 6th. HC Wainwright restated a “buy” rating on shares of ASLAN PHARMACEU/ADR in a report on Thursday, January 24th.
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last posted its earnings results on Friday, March 22nd. The company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02. Equities analysts forecast that ASLAN PHARMACEU/ADR will post -0.73 EPS for the current fiscal year.
A hedge fund recently bought a new stake in ASLAN PHARMACEU/ADR stock. FNY Investment Advisers LLC acquired a new stake in ASLAN PHARMACEU/ADR (NASDAQ:ASLN) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 26,402 shares of the company’s stock, valued at approximately $104,000. FNY Investment Advisers LLC owned about 0.08% of ASLAN PHARMACEU/ADR as of its most recent filing with the SEC. 9.36% of the stock is owned by institutional investors and hedge funds.
About ASLAN PHARMACEU/ADR
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
See Also: Diversification Important in Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.